ARGENTA
27.6.2022 09:01:10 CEST | Business Wire | Press release
Argenta today announced that Paul Fry will join the company as its new Chief Financial Officer, starting immediately. To ensure a smooth transition, Paul will work closely with former CFO Chris O’Donnell until late August.
The CFO role is being relocated from New Zealand to London to enable the CEO and CFO to work closely together in the same time zone, and to be closer to customers and new commercial opportunities.
Chris O’Donnell, who has served as Argenta’s CFO since 2018, is supportive of the decision and has decided to stay in New Zealand. He stepped down from his role on June 24 and will stay on until August 26 to support with the transition. Chris has played a leading role in the success and growth of Argenta, providing skilful oversight to key projects including the transition of ownership to KKR and the acquisition of Klifovet.
Paul Fry has extensive financial experience across several industries including biotech, pharmaceuticals, and telecommunications. Prior to joining Argenta, he was Chief Financial Officer of Vectura Group plc, an industry-leading inhaled drug delivery specialist which was listed on the main market of the London Stock Exchange until 2021. In his time with the company, he played an instrumental role in almost doubling its market valuation.
Before Vectura, Paul was Chief Financial Officer of Immunocore Limited, a leading biotech company focused on the development of a new class of immunotherapeutic drugs based on proprietary T-cell receptor (TCR) technology. He also served as Director of Global Finance Operations at Vodafone plc and spent more than 25 years at GSK, where he held several senior leadership roles.
Will Downie, CEO of Argenta, said: “I am delighted to welcome Paul to Argenta. His proven track record and extensive experience, combined with his strategic financial expertise and outstanding leadership qualities, will have a significant impact on the company. I am excited to partner with Paul to help drive long-term growth and scale for the organization.
“I would also like to take this opportunity to express my gratitude to Chris O’Donnell for his commitment, partnership, and financial stewardship in the time we have worked together. Chris has helped to lay the solid foundation that supports the company's ambitious strategy.”
Paul Fry said: “It is an exciting time to enter the animal health industry and I am delighted to be joining Argenta. The company has a unique offering, strong track record and the potential for significant growth for many years to come. I feel privileged to be able to contribute to this and to have the opportunity to serve Argenta’s customers, team members and shareholders.”
Paul holds a degree from Oxford University and is a member of the Chartered Institute of Management Accounts. He is also a Non-executive Director and Chair of the Audit Committee at Avacta plc, an AIM-listed biotech company developing diagnostics and new oncology therapies.
About Argenta
Argenta is the only combined global Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) dedicated to animal health. Founded in 2006 in New Zealand, Argenta’s talented, diverse, and committed employees are driven to deliver excellence in animal health to customers around the world. With research and GMP manufacturing operations in New Zealand, the United States, the United Kingdom, and Germany, Argenta operates from ‘Molecule to Market’ in partnership with its customers to support their R&D, regulatory, clinical research, and manufacturing needs along the veterinary product development journey. For more information about Argenta, please visit www.argentaglobal.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220626005001/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Brings Flagship Kinexions Conference to India, Showcasing Growing Market Momentum17.11.2026 02:30:00 CET | Press release
Inaugural event features leaders from Tata Consumer Products and Sun Pharma, highlighting India's growing role in global supply chain innovation Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today opened its first-ever Kinexions India conference in Mumbai, highlighting the company's growing presence in the country and India's importance to its global innovation and customer delivery operations. With teams in Chennai and Bangalore supporting product development, engineering, professional services and customer success, India plays an important role in Kinaxis' global operations. The company continues to invest in research and development in India, strengthening its engineering and innovation capabilities to support the next generation of AI and supply chain orchestration technologies. "India plays an important role in how we innovate and support customers around the world," said Razat Gaurav, CEO of Kinaxis. "Bringing Kinexions here for
Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa16.11.2026 22:30:00 CET | Press release
European Commission approval based on data from Phase 3 STOP-HS1 and STOP-HS2, which showed that Povofortay® (povorcitinib) met the primary endpoint at Week 12 and delivered clinically meaningful, durable responses through Week 54 and was well tolerated 1,2 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). “The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease,” 2,3 said Bill Meury, Chief Executive Officer, Incyte."As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” The approval is based on res
Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 22:00:00 CET | Press release
Bhatt to lead enterprise technology strategy, AI deployment, and cyber and information security in Executive Leadership Team role Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise work
Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 22:00:00 CET | Press release
Radiation-resilient Lattice Nexus FPGAs have operated as specified in TESAT optical communication terminals since 2025 Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platf
New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 18:00:00 CET | Press release
New Survey of More Than 4,000 Players Finds 78% Play More During the Holidays and 82.5% Would Watch a Rewarded Ad in Exchange for a Bonus Offer Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an aud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
